Andrew Tsai
Stock Analyst at Jefferies
(0.19)
# 4,142
Out of 4,842 analysts
18
Total ratings
20%
Success rate
-35.61%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Tsai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCKT Rocket Pharmaceuticals | Downgrades: Hold | $29 → $2.5 | $2.48 | +0.81% | 2 | May 28, 2025 | |
| AXSM Axsome Therapeutics | Initiates: Buy | $200 | $102.99 | +94.19% | 1 | Apr 7, 2025 | |
| BEKE KE Holdings | Maintains: Overweight | $19 → $27 | $18.41 | +46.66% | 2 | Mar 19, 2025 | |
| SRPT Sarepta Therapeutics | Initiates: Buy | $165 | $37.23 | +343.19% | 1 | Oct 21, 2024 | |
| RLMD Relmada Therapeutics | Upgrades: Buy | $3.5 → $13 | $0.72 | +1,693.35% | 2 | Sep 17, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | $35 | $9.51 | +268.03% | 1 | Jul 2, 2024 | |
| ANRO Alto Neuroscience | Initiates: Buy | $33 | $2.72 | +1,113.24% | 1 | Feb 27, 2024 | |
| VTGN Vistagen Therapeutics | Upgrades: Buy | $0.2 → $15 | $2.53 | +492.89% | 2 | Dec 7, 2023 | |
| LXRX Lexicon Pharmaceuticals | Initiates: Hold | $3 | $0.70 | +328.94% | 1 | Mar 7, 2023 | |
| ATHA Athira Pharma | Downgrades: Hold | $32 → $3 | $0.29 | +942.03% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $7.89 | +153.49% | 1 | Feb 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $2.31 | +1,068.83% | 1 | Sep 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $16 → $23 | $28.49 | -19.27% | 1 | Jun 1, 2020 |
Rocket Pharmaceuticals
May 28, 2025
Downgrades: Hold
Price Target: $29 → $2.5
Current: $2.48
Upside: +0.81%
Axsome Therapeutics
Apr 7, 2025
Initiates: Buy
Price Target: $200
Current: $102.99
Upside: +94.19%
KE Holdings
Mar 19, 2025
Maintains: Overweight
Price Target: $19 → $27
Current: $18.41
Upside: +46.66%
Sarepta Therapeutics
Oct 21, 2024
Initiates: Buy
Price Target: $165
Current: $37.23
Upside: +343.19%
Relmada Therapeutics
Sep 17, 2024
Upgrades: Buy
Price Target: $3.5 → $13
Current: $0.72
Upside: +1,693.35%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $9.51
Upside: +268.03%
Alto Neuroscience
Feb 27, 2024
Initiates: Buy
Price Target: $33
Current: $2.72
Upside: +1,113.24%
Vistagen Therapeutics
Dec 7, 2023
Upgrades: Buy
Price Target: $0.2 → $15
Current: $2.53
Upside: +492.89%
Lexicon Pharmaceuticals
Mar 7, 2023
Initiates: Hold
Price Target: $3
Current: $0.70
Upside: +328.94%
Athira Pharma
Jun 23, 2022
Downgrades: Hold
Price Target: $32 → $3
Current: $0.29
Upside: +942.03%
Feb 1, 2022
Initiates: Buy
Price Target: $20
Current: $7.89
Upside: +153.49%
Sep 1, 2021
Initiates: Buy
Price Target: $27
Current: $2.31
Upside: +1,068.83%
Jun 1, 2020
Assumes: Buy
Price Target: $16 → $23
Current: $28.49
Upside: -19.27%